about
Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia.The prognostic significance of pneumothorax in patients with idiopathic pulmonary fibrosis.Utility of serum Aspergillus-galactomannan antigen to evaluate the risk of severe acute exacerbation in chronic obstructive pulmonary disease.IL-17A Attenuates IFN-λ Expression by Inducing Suppressor of Cytokine Signaling Expression in Airway EpitheliumUsing fractional exhaled nitric oxide to guide step down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysisOnce-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trialClinical significance of serum S100 calcium-binding protein A4 in idiopathic pulmonary fibrosisEfficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched AnalysisEfficacy of corticosteroid and intravenous cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: A propensity score-matched analysisClinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease
P50
Q47191410-A3F30195-B023-468D-B792-3C8B101CA08DQ48318286-602F0B40-C4AA-4120-B948-5C8383D792EFQ55489630-07FFD8F2-385F-4D0D-BB4D-3DF2FE2F74EBQ57464674-61E22A46-304D-47AC-B7D9-1A760F2C53EEQ90089438-7F6B26D6-DC86-42FE-9B91-668F9807DF6CQ90398105-31EFA1A7-0AE6-428B-B9B6-640077EEC127Q90613150-43E5109E-E3C1-4658-A1A8-A4504726718BQ91062137-8A47B27A-A690-4DE1-BB8D-2A8477585038Q91896259-26E93CF4-601D-430D-9F9B-A49AEC51A7E6Q92051303-F60FD055-6941-4FCB-BA90-8676AAE88689
P50
description
researcher
@en
name
Tomoyuki Fujisawa
@en
type
label
Tomoyuki Fujisawa
@en
prefLabel
Tomoyuki Fujisawa
@en
P31
P496
0000-0002-8809-1781